Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVKQT8)

• Drug Name: SALACINOL Drug Info
• Synonyms: SALACINOL; 200399-47-9; CHEMBL239249; CHEMBL1208974; AC1O52U7; BDBM50180585; BDBM50330955; FT-0674499; 1,4-dideoxy-1,4-{(S)-[(2S,3S)-2,4-dihydroxy-3-(sulfooxy)butyl]episulfoniumylidene}-D-arabinitol; 1,4-Dideoxy-1,4-[(S)-[(2S,3S)-2,4-dihydroxy-3-(sulfooxy)butyl]episulfoniumylidene]-D-arabinitol Inner Salt; [(2S,3S)-4-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]-1,3-dihydroxybutan-2-yl] sulfate
• Cross-matching ID:
  PubChem CID: 6451151
  CAS Number: CAS 200399-47-9
  TTD Drug ID: DMVKQT8

Molecule-Related Drug Atlas

Drug(s) Targeting Lysosomal alpha-glucosidase (GAA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avalglucosidase alfa	DMPW5UF	Pompe disease	5C51.3	Approved	[3]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[4]
BMN-701	DM94Y6O	Pompe disease	5C51.3	Phase 3	[5]
AT845	DMZJIIB	Pompe disease	5C51.3	Phase 2	[6]
SPK-3006	DMK9DG5	Pompe disease	5C51.3	Phase 1/2	[7]
GZ402666	DMGO6M1	Pompe disease	5C51.3	Phase 1	[8]
5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one	DMAJWLD	Pompe disease	5C51.3	Preclinical	[9]
Alpha-Homonojirimycin	DMT17H0	Discovery agent	N.A.	Investigative	[4]
7-O-b-D-Glucopyranosyl-a-homonojirimycin	DM8IY3D	Discovery agent	N.A.	Investigative	[4]
VALIOLAMINE	DM2VQN5	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting Intestinal maltase-glucoamylase (MGAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voglibose	DMUBP9O	Diabetic complication	5A2Y	Approved	[10]
Acarbose	DMRM3AW	Diabetic complication	5A2Y	Approved	[11]
Miglitol	DMXBQAM	Diabetic complication	5A2Y	Approved	[12]
Rh-alphaglucosidase	DMNF0G8	Pompe disease	5C51.3	Approved	[13]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[14]
Alpha-glucosidase	DM2RTGP	Muscle disease	FB3Z	Phase 3	[15]
PAZ-320	DMU0812	Type-2 diabetes	5A11	Phase 2	[16]
SC-49483	DM180VX	Acquired immune deficiency syndrome	1C62.3	Phase 2	[17]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[18]
Celgosivir	DMD1V7I	Dengue fever	1D2Z	Phase 1/2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Intestinal maltase-glucoamylase (MGAM)	TTXWASR	MGA_HUMAN	Inhibitor	[1]
Lysosomal alpha-glucosidase (GAA)	TTLPC70	LYAG_HUMAN	Inhibitor	[2]

References

• [1] Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8.
• [2] Alpha-glucosidase inhibitor from Kothala-himbutu (Salacia reticulata WIGHT). J Nat Prod. 2008 Jun;71(6):981-4.
• [3] ClinicalTrials.gov (NCT02782741) Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET). U.S. National Institutes of Health.
• [4] In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
• [5] Clinical pipeline report, company report or official report of BioMarin Pharma.
• [6] Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity. EMBO Mol Med. 2022 Jan 11;14(1):e13968.
• [7] Clinical pipeline report, company report or official report of Spark Therapeutics
• [8] ClinicalTrials.gov (NCT01898364) Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.. U.S. National Institutes of Health.
• [9] 5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)indolin-2-one Analogs as Inhibitors of Acid alpha-Glucosidase for Potential Chaperone Treatment of Pompe Disease or Intervention for Diabetes Mellitus Type 2. N.A.. N.A.
• [10] Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [12] Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29.
• [13] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [14] Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
• [16] Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022.
• [17] Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Toxicol Pathol. 1996 Sep-Oct;24(5):531-8.
• [18] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [19] Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.Curr Opin Investig Drugs.2009 Aug;10(8):860-70.